Tubocurarine

Revision as of 13:10, 13 April 2015 by Rabin Bista (talk | contribs)
Jump to navigation Jump to search
Tubocurarine
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa682860
Pregnancy
category
  • D
Routes of
administration		IV
ATC code
Legal status
Legal status
  • World wide Rx-only medication
Pharmacokinetic data
Bioavailability100% (IV)
Protein binding50%
Elimination half-life1-2 hours
Identifiers
CAS Number
  • 57-95-4 ☒N (chloride hydrochloride)
    6989-98-6 (chloride hydrochloride pentahydrate)
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC37H42Cl2N2O6
Molar mass624.765 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Tubocurarine

Articles

Most recent articles on Tubocurarine

Most cited articles on Tubocurarine

Review articles on Tubocurarine

Articles on Tubocurarine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tubocurarine

Images of Tubocurarine

Photos of Tubocurarine

Podcasts & MP3s on Tubocurarine

Videos on Tubocurarine

Evidence Based Medicine

Cochrane Collaboration on Tubocurarine

Bandolier on Tubocurarine

TRIP on Tubocurarine

Clinical Trials

Ongoing Trials on Tubocurarine at Clinical Trials.gov

Trial results on Tubocurarine

Clinical Trials on Tubocurarine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tubocurarine

NICE Guidance on Tubocurarine

NHS PRODIGY Guidance

FDA on Tubocurarine

CDC on Tubocurarine

Books

Books on Tubocurarine

News

Tubocurarine in the news

Be alerted to news on Tubocurarine

News trends on Tubocurarine

Commentary

Blogs on Tubocurarine

Definitions

Definitions of Tubocurarine

Patient Resources / Community

Patient resources on Tubocurarine

Discussion groups on Tubocurarine

Patient Handouts on Tubocurarine

Directions to Hospitals Treating Tubocurarine

Risk calculators and risk factors for Tubocurarine

Healthcare Provider Resources

Symptoms of Tubocurarine

Causes & Risk Factors for Tubocurarine

Diagnostic studies for Tubocurarine

Treatment of Tubocurarine

Continuing Medical Education (CME)

CME Programs on Tubocurarine

International

Tubocurarine en Espanol

Tubocurarine en Francais

Business

Tubocurarine in the Marketplace

Patents on Tubocurarine

Experimental / Informatics

List of terms related to Tubocurarine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tubocurarine (also known as d-tubocurarine or DTC) is a toxic alkaloid and skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. Unlike a number of other related skeletal muscle relaxants, it is now rarely considered clinically to facilitate endotracheal intubation.

Tubocurarine is classified as a long-duration,[1] antagonist for Nicotinic acetylcholine receptor.[2] It is the active agent of one of the forms of curare.

Currently, tubocurarine is rarely used as an adjunct for clinical anesthesia because safer alternatives, such as cisatracurium and rocuronium, are available.

History

Tubocurare is a naturally occurring mono-quaternary alkaloid obtained from the bark of the South American plant Chondrodendron tomentosum, a climbing vine known to the European world since the Spanish conquest of South America. Curare had been used as a source of arrow poison by South American natives to hunt animals, and they were able to eat the animals' contaminated flesh subsequently without any untoward effects, because tubocurarine cannot easily cross mucous membranes. Tubocurarine is thus effective only if given parenterally, as demonstrated by Bernard, who also showed the site of its action was at the neuromuscular junction.[3] Virchow and Munter confirmed the paralyzing action was limited to voluntary and not involuntary muscles.[4] Thus, a conscious individual administered this agent will be unable to move any voluntary muscles, including the diaphragm: a large enough dose will therefore result in death from respiratory failure unless artificial ventilation is initiated.

The word "curare" comes from the South American Indian name for the arrow poison, ourare. Presumably, the initial syllable was pronounced with a heavy glottal stroke. Tubocurarine is so-called because the plant samples containing the curare were stored and shipped to Europe in tubes. Likewise, curare stored in calabash containers was called calabash curare.

Structurally, tubocurarine is a benzylisoquinoline derivative. For many years, its structure, when first elucidated in 1948,[5] was wrongly thought to be bis-quaternary: in other words, it was thought to be an N,N-dimethylated alkaloid. In 1970, the correct structure was finally established,[6] showing one of the two nitrogens to be tertiary, actually a mono-N-methylated alkaloid.

Griffith and Johnson are credited with pioneering the formal clinical introduction of tubocurarine as an adjunct to anesthetic practice on 23 January 1942, at the Montreal Homeopathic Hospital.[7] In this sense, tubocurarine is the prototypical adjunctive neuromuscular blocking agent. However, others before Griffith and Johnson had attempted use of tubocurare in several situations:[8][9][10] some under controlled study conditions[11][12] while others not quite controlled and remained unpublished.[13] Regardless, all in all some ~30,000 patients had been given tubocurare by 1941, although it was Griffith and Johnson's 1942 publication[7] that provided the impetus to the standard use of neuromuscular blocking agents in clinical anesthestic practice - a revolution that rapidly metamorphosized into the standard practice of "balanced" anesthesia: the triad of barbiturate hypnosis, light inhalational anesthesia and muscle relaxation.[14] The technique as described by Gray and Halton was widely known as the "Liverpool technique",[14] and became the standard anesthetic technique in England in the 1950s and 1960s for patients of all ages and physical status. Present clinical anesthetic practice still employs the central principle of balanced anesthesia though with some differences to accommodate subsequent technological advances and introductions of new and better gaseous anesthetic, hypnotic and neuromuscular blocking agents, and tracheal intubation, as well as monitoring techniques that were nonexistent in the day of Gray and Halton: pulse oximetry, capnography, peripheral nerve stimulation, noninvasive blood pressure monitoring, etc.

Biosynthesis

Tubocurarine biosynthesis involves a radical coupling of two enantiomeric tetrahydrobenzylisoquinolines, more specifically, the two enantiomers of N-methyl-coclaurine. (R) and (S)-N-methyl-coclaurine come from a Mannich-like reaction between dopamine and 4-hydroxyphenyl-acetaldehyde, facilitated by norcoclaurine synthase (NCS). Both dopamine and 4-hydroxyphenylacetyladehyde originate from L-tyrosine. The biosynthetic pathway is described in more detail in the figures. Methylation of the amine and hydroxyl substituents are facilitated by S-adenosyl methionine (SAM).[15]

Clinical pharmacology and pharmacokinetics

Tubocurarine has a time of onset of 300 seconds or more (which is relatively slow among neuromuscular-blocking drugs), and has a duration of action of 60 to 120 minutes (which is relatively long time).[16]

It also causes histamine release,[17] now a recognized hallmark of the tetrahydroisioquinolinium class of neuromuscular blocking agents. The amount of histamine release in some instances following tubocurarine administration is such that it is contraindicated in asthmatics and patients with allergies.[citation needed] However, the main disadvantage in the use of tubocurarine is its significant ganglion-blocking effect,[18] that manifests as hypotension,[19] in many patients; this constitutes a relative contraindication to its use in patients with myocardial ischaemia.

Because of the shortcomings of tubocurare, much research effort was undertaken soon after its clinical introduction to find a suitable replacement. The efforts unleashed a multitude of compounds borne from structure-activity relations developed from the tubocurare molecule. Some key compounds that have seen clinical use are identified in the muscle relaxants template box below. Of the many tried as replacements, only a few enjoyed as much popularity as tubocurarine: pancuronium, vecuronium, rocuronium, atracurium, and cisatracurium. Succinylcholine is a widely used paralytic drug which acts by activating, instead of blocking, the ACh receptor.

The potassium channel blocker tetraethylammonium (TEA) has been shown to reverse the effects of tubocurarine. It is thought to do so by increasing ACh release, which counteracts the antagonistic effects of tubocurarine on the ACh receptor.

References

  1. ↑ Thompson MA (1980). "Muscle relaxant drugs". Br J Hosp Med. 23 (2): 153–4, 163–4, 167–8 passim. PMID 6102875.
  2. ↑ Wenningmann I, Dilger JP (October 2001). "The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium". Molecular Pharmacology. 60 (4): 790–6. PMID 11562442.
  3. ↑ Bernard C (1856). "Analyse physiologie des propriétés des actions de curare et de la nicotine sure systèmes musculaire et nerveux au moyen du curare". Compt. Rend. 43: 305–319.
  4. ↑ Bechter AM (1977). "The civilizing of curare: a history of its development and introduction into anesthesiology". Anesth Analg. 56 (2): 305–319. doi:10.1213/00000539-197703000-00032. PMID 322548.
  5. ↑ King H (1948). "64. Curare alkaloids. Part VII. Constitution of dextrotubocurarine chloride". J Chem Soc: 265. doi:10.1039/jr9480000265.
  6. ↑ Everett AJ, Lowe LA, Wilkinson S (1970). J Chem Soc, Chem Commun: 1020. Missing or empty |title= (help)
  7. ↑ 7.0 7.1 Griffith HR, Johnson GE (1942). "The use of curare in general anesthesia". Anesthesiol. 3 (4): 418–420. doi:10.1097/00000542-194207000-00006.
  8. ↑ Läwen A (1912). "Ueber die verbindung der lokakanaesthesie und epidurale injektion anesthesiernder losungen bei tabischen magenkrisen". Beitr Klin Chir. 80: 168–189.
  9. ↑ Wilkinson DJ (1991). "Dr. F.P. de Caux - the first user of curare for anaesthesia in England". Anaesthesia. 46 (1): 49–51. doi:10.1111/j.1365-2044.1991.tb09317.x. PMID 1996757.
  10. ↑ Bennett AE (1941). "Curare: a preventive of traumatic complications in electroconvulsive shock therapy". Am J Psychiatry. 97: 1040–1060.
  11. ↑ West R (1984). "An excursion into pharmacology: curare in medicine". Medical History. 28 (4): 391–405. doi:10.1017/s0025727300036279. PMC 1140012. PMID 6390032.
  12. ↑ Burman MS (1939). "Therapeutic use of curare and erythroidine hydrochloride for spastic and dystonic states". Arch Neurol Psychiat. 41: 307–327. doi:10.1001/archneurpsyc.1939.02270140093008.
  13. ↑ Bevan DR. (1992) "Curare". In: Maltby JR, Shephard DAE (Eds.), Harold Griffith - His Life and Legacy; Suppl. to Can J Anaesth Vol. 39 (1); 49-55.
  14. ↑ 14.0 14.1 Gray TC, Halton J (1946). "Technique for the use of d-tubocurarine chloride with balanced anaesthesia". Br Med J. 2: 293–295. PMID 20996123.
  15. ↑ Dewick, P. M. Medicinal Natural Products; a Biosynthetic Approach. 3rd ed.; John Wiley and Sons Ltd.: 2009.
  16. ↑ Page 151 in: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. OCLC 51622037.
  17. ↑ Maclagen J. (1976) In: Zaimis E. (Ed.), "Neuromuscular Junction". Hand. Exp. Pharm.; Vol. 42; Springer-Verlag, Berlin: 421-486.
  18. ↑ Bowman WC, Webb SN (1972). "Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat". J Pharm Pharmacol. 24 (10): 762–72. doi:10.1111/j.2042-7158.1972.tb08880.x. PMID 4403972.
  19. ↑ Coleman AJ, Downing JW, Leary WP, Moyes DG (1972). "The immediate cardiovascular effects of pancuronium, alcuronium and tubocurarine in man". Anaesthesia. 27 (4): 415–22. doi:10.1111/j.1365-2044.1972.tb08247.x. PMID 4264060.

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Tubocurarine&oldid=1086397"